Vaccine development involves the creation of immunological interventions designed to prevent infectious diseases by inducing protective immunity, while antibody-based therapies leverage monoclonal antibodies (mAbs) to treat infections, neutralize pathogens, and modulate the immune system. Together, these fields represent cutting-edge approaches in the battle against infectious diseases, including viral, bacterial, and parasitic infections.
Vaccine development and antibody-based therapies have revolutionized the management of infectious diseases in recent years, with remarkable success in combating diseases like COVID-19, Ebola, and influenza. This session will explore the science, challenges, and innovations in both fields, highlighting the path from discovery to clinical application.
Key topics covered include:
- Vaccine Platforms: mRNA, viral vector, protein subunit, and live-attenuated vaccines
- Adjuvants and Immune Modulation: Enhancing vaccine efficacy and longevity
- Antibody-Based Therapies: Monoclonal antibodies, convalescent plasma, and engineered antibodies
- Challenges in Vaccine Development: Rapid manufacturing, distribution, and global equity
- Vaccine Hesitancy and Public Health Policy
- Emerging Infectious Diseases: Novel strategies for vaccine and antibody-based therapy development
- Therapeutic Antibodies in Infectious Disease Management: Targeting viral and bacterial pathogens
- Global Collaboration and Partnerships: CEPI, GAVI, and other global health initiatives
This session aims to bring together vaccine developers, immunologists, biopharmaceutical researchers, public health experts, and regulatory authorities to share the latest advancements and strategies in the development of vaccines and antibody-based treatments.